Evidence map›Paper›PMID 39609559›Full record

ArticleNature biomedical engineering2025

Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates.

Yu Zhao, Donghui Song, Zeyu Wang, Qingqing Huang, Fan Huang, Zhongfeng Ye, Douglas Wich, Mengting Chen, Jennifer Khirallah, Shuliang Gao and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu ZhaoDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Donghui SongDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Zeyu WangDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Qingqing HuangKey Laboratory of Functional Polymer Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin, China.
Fan HuangChinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Zhongfeng YeDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Douglas WichDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Mengting ChenDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Jennifer KhirallahDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Shuliang GaoDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA.
Yang LiuKey Laboratory of Functional Polymer Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin, China.
Qiaobing XuDepartment of Biomedical Engineering, Tufts University, Medford, MA, USA. qiaobing.xu@tufts.edu.ORCID http://orcid.org/0000-0001-7323-7795

Funding

U.S. Department of Health & Human Services | National Institutes of Health (NIH) EB027170-01
6 · The paper itself

Abstract

The activation of cytotoxic T cells against tumour cells typically requires the cross-presentation, by antigen-presenting cells (and via major histocompatibility complex class I molecules), of an epitope derived from a tumour antigen. A critical step in antigen processing is the proteolysis of tumour antigens mediated by the ubiquitin-proteasome pathway. Here we describe a tumour vaccine leveraging targeted antigen degradation to augment antigen processing and cross-presentation. Analogous to proteolysis-targeting chimaeras, the vaccine consists of lymph-node-targeting lipid nanoparticles encapsulated with tumour antigens pre-conjugated with ligands that can bind to E3 ubiquitin ligases. In mice with subcutaneous human melanoma or triple-negative breast cancer, or with orthotopic mouse Lewis lung carcinoma or clinically inoperable mouse ovarian cancer, subcutaneously delivered vaccines prepared using tumour lysate proteins elicited antigen-specific adaptive immunity and immunological memory, and inhibited tumour growth, metastasis and recurrence, particularly when combined with immune checkpoint inhibition.

Indexed as

Antigens, NeoplasmCancer VaccinesVaccinationAnimalsAntigen PresentationCell Line, TumorFemaleHumansMiceMice, Inbred C57BLNanoparticlesProteolysisAntigens, NeoplasmCancer Vaccines

Identifiers

PMID39609559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.